Dr Reddys Laboratories Ltd

BSE :500124 NSE :DRREDDY Sector : Pharmac..
1,107.95
Change: 2.80(0.25%)
Buy Sell SIP
52 week Low
1,092.45
52 week High
1,421.49
Day low
1,095.05
Day high
1,110.25
Prev Close
1,105.15
Open
1,105.15
6M return
-16.83%
1Y return
-12.12%
MCap(Rs. in Cr.)
92,452.24
Total Volume
12,99,174
Face Value : 1
Listed Since
PE Ratio

Is the price-earnings ratio for valuing a company that measures its current share price relative to its earnings per share.

P/E RATIO
0
EPS

The earnings per share ratio is a portion of company's net profit allocated for each outstanding share. It is calculated by deducting preferred stock divided from the net income of the company divided by the number of outstanding shares.

EPS
0
PRICE/BOOK

Price-to-book ratio is used to compared the company's current market price with its book value.

PRICE/BOOK
Deliverable

These are the acutal number of shares that are traded on delivery based, meaning transfered from one person to another during the day's trade.

DELIVERABLES
0
DIV YIELD.(%)

Dividend Yield measures the quantum of cash dividends paid to shareholders in a financial year relative to the market value of the per share.

DIV YIELD.(%)
0

Company Details

Check out the key parameters of the company to understand the financial health and stock performance

Key Level

Resistance 1
-
Resistance 2
-
Support 1
-
Support 2
-

Moving Average

20 Days
-
50 Days
-
100 Days
-
200 Days
-
Growth in 3 years

Sales


Sales Industry Avg


PAT


PAT Industry Avg


No data available
No data available


Relative to Sensex rtn in 3 year


Relative to Nifty rtn in 3 year


Relative to top 3 MF rtn in 3 year


2016 2014 2014
Sales 59.91 59.91 59.91
Gross Profit 60.14 60.14 60.14
Operating Profit 6.14 6.14 6.14
Sales 59.91 59.91 59.91
Gross Profit 60.14 60.14 60.14
Operating Profit 6.14 6.14 6.14

Peer Companies

A quick glance on how stocks from the same sector have performed along with some key parameters

Dr Reddy`s Labs
1,107.95
Change: 2.80 (0.25%)
1 Year return
-12.12%
Risk (Std Dev)
0.08%
PE Ratio
17.21066
MCap( in Cr.)
92,452.24
BUY SELL
Sun Pharma.Inds.
1,683.45
Change: 6.60 (0.39%)
1 Year return
8.01%
Risk (Std Dev)
0.07%
PE Ratio
34.25244
MCap( in Cr.)
4,03,916.05
BUY SELL
Divi`s Lab.
5,620.45
Change: -46.70 (-0.82%)
1 Year return
61.52%
Risk (Std Dev)
0.06%
PE Ratio
72.17827
MCap( in Cr.)
1,49,205.29
BUY SELL
Cipla
1,461.90
Change: 7.60 (0.52%)
1 Year return
-0.64%
Risk (Std Dev)
0.04%
PE Ratio
23.65814
MCap( in Cr.)
1,18,065.23
BUY SELL
Torrent Pharma.
3,056.05
Change: -40.45 (-1.31%)
1 Year return
14.72%
Risk (Std Dev)
0.06%
PE Ratio
55.58797
MCap( in Cr.)
1,03,425.97
BUY SELL
View More

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

 

If I had made
investment of  
in
Months Ago
My investment would be worth 0 with a of 0%

Our Research Reports

Stocks and sector-wise Research Reports by HDFC securities help you analyse, understand and take a informed investment decision.

Institutional Reports 14 Jan 2025 1:51 PM
Pharma and Healthcare (Q3FY25E): Growth momentum, margin visibility stay intact
The India Pharma & Healthcare sector is expected to see steady growth in Q3FY25E. We project sales/EBITDA growth of 11%/13% YoY for our coverage universe. Our assumptions are: (1) pharma coverage wil..
Institutional Reports 06 Nov 2024 6:51 AM
HSIE Results Daily: Titan, ABB India, Mankind Pharma, Dr Reddy’s Laboratories, Berger Paints, KEC International, V-MART Retail, Sai Silk (Kalamandir)
Titan: Consolidated jewellery sales (ex-bullion) grew 27% YoY to INR117.8bn (HSIE: in-line). Gold jewellery demand witnessed a step-up jump post the Jul-24 customs duty (CD) cut. This gold rush laste..
Institutional Reports 09 Oct 2024 9:00 PM
Pharma and Healthcare (Q2FY25E Results Preview): Steady Q2, Revlimid to normalise
The India Pharma & Healthcare sector is expected to maintain its growth momentum in Q2FY25E. We project sales/EBITDA growth of 11%/15% YoY for our coverage universe. Our assumptions are: (1) Pharma c..
View More

News

Stay tuned to the latest developments and happenings in the company.

Dr. Reddy`s recalls Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL in US

Dr. Reddy`s Laboratories is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75% Sodium Chloride Injection, 1,000 mg/100 mL (10 mg/m....

13 Mar 2025 18:46

Dr Reddys Laboratories allots 11,250 equity shares under ESOS

Dr Reddys Laboratories has allotted 11,250 equity shares under ESOS on 06 March 2025. Powered by Capital Market - Live News

06 Mar 2025 19:16

Dr Reddys Laboratories allots 20,155 equity shares under ESOS

Dr Reddys Laboratories has allotted 20,155 equity shares of Re.1/- each of the Company, fully paid up, on 14 February 2025, to eligible employees purs....

14 Feb 2025 18:24

Dr Reddy`s Laboratories consolidated net profit rises 2.38% in the December 2024 quarter

Net profit of Dr Reddy`s Laboratories rose 2.38% to Rs 1413.70 crore in the quarter ended December 2024 as against Rs 1380.90 crore during the previou....

23 Jan 2025 17:55

Dr Reddy`s Laboratories consolidated net profit declines 15.28% in the September 2024 quarter

Net profit of Dr Reddy`s Laboratories declined 15.28% to Rs 1255.70 crore in the quarter ended September 2024 as against Rs 1482.20 crore during the p....

05 Nov 2024 17:09

Dr Reddy`s Laboratories consolidated net profit declines 0.90% in the June 2024 quarter

Net profit of Dr Reddy`s Laboratories declined 0.90% to Rs 1392.40 crore in the quarter ended June 2024 as against Rs 1405.00 crore during the previou....

27 Jul 2024 16:55

View More
Subscribe for our
newsletter
Open Account Now